SeQuent Scientific reports strong Q2 results and merger approval
pre-market1 source ↓written by the desknot a recommendation
- for Q2
- 15% year-on-year growth
- margin rising
- 49.7%
- year-on-year
- 18% growth
SeQuent Scientific Limited reported revenue of ₹4,240 million, reflecting a 15% year-on-year growth for Q2. The EBITDA margin improved to 15.5%, with gross margin rising to 49.7%. Additionally, the company secured NCLT approval for its merger, enhancing its strategic position in the animal health sector. 📈
The formulations segment, contributing 75% of sales, achieved 18% growth year-on-year, driven by strong performances in Europe and emerging markets.
Not investment advice. For informational purposes only.